- Sugen is to expand clinical trials of SU101 in the treatment ofprostate, ovarian and non-small cell lung cancer based on encouraging clinical data from Phase I/II trials. In addition, the company says that it will now file for approval of SU101 as a therapy for refractory malignant glioma. In a Phase II trial, 43% of patients exhibited a partial response (tumor shrinkage of more than 50% or stable disease).
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
7 day trial access
Become a subscriber
Or £77 per month
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Sign up to receive email updates
Join industry leaders for a daily roundup of biotech & pharma news
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze